This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
725PEfficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis. (23rd October 2018)
Record Type:
Journal Article
Title:
725PEfficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis. (23rd October 2018)
Main Title:
725PEfficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis